CAMBRIDGE, Mass.--(BUSINESS WIRE)--Warp Drive Bio today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 6 to 9, 2015 at the Hynes Convention Center in Boston.
The presentation, “Drugging RAS Into Oblivion” will be given during the plenary session “Update on Targeting RAS and Cancer” on Saturday, November 7, 2015 between 10:20 a.m. – 12:20 p.m., by Greg Verdine, Ph.D., Founder, President and Chief Scientific Officer of Warp Drive Bio.
About Warp Drive Bio
Warp Drive Bio is exploiting the molecules and mechanisms of nature to create transformative medicines. The company operates on the core principle that nature is the world’s most powerful inventor of new drugs, unconstrained by the mechanistic and synthetic limitations of traditional medicinal chemistry. Warp Drive Bio is deploying its proprietary Genomic Mining and SMARTTM (Small Molecule Assisted Receptor Targeting) platforms to discover novel medicines that have the potential to make a significant difference in patients’ lives. The company was launched in 2012 through a strategic partnership with Sanofi and with financing from Third Rock Ventures and Greylock Partners. For more information, please visit www.warpdrivebio.com.
